Hsp-90-associated oncoproteins: Multiple targets of geldanamycin and its analogs

Leukemia

Volumn 16, Issue 4, 2002, Pages 455-462

  Blagosklonny, M V ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Geldanamycin; Heat shock proteins; Molecular therapeutics; Oncogenes

Indexed keywords

BCR ABL PROTEIN; DOXORUBICIN; ESTROGEN RECEPTOR; FLT3 LIGAND; GELDANAMYCIN; GLUCOCORTICOID RECEPTOR; GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN 90; HERBIMYCIN A; IMATINIB; ONCOPROTEIN; PROGESTERONE RECEPTOR; PROTEASOME; PROTEIN KINASE INHIBITOR; PROTEIN KINASE P60; PROTEIN P53; RADICICOL; RAF PROTEIN; STEROID RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CELL DIFFERENTIATION; CELL KILLING; CELL STRAIN 3T3; CHRONIC MYELOID LEUKEMIA; DOG; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG TARGETING; FATIGUE; FEVER; GENE MUTATION; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; LIVER DISEASE; MOUSE; NONHUMAN; ONCOGENE C ERB; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; RETROSPECTIVE STUDY; REVIEW; TUMOR CELL; VOMITING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BENZOQUINONES; CLINICAL TRIALS; GROWTH INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; NEOPLASMS; ONCOGENE PROTEINS; PROTEIN KINASES; QUINONES; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 85047695528     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402415     Document Type: Review

References (116)

1. Effect of anti-leukemic drugs on cell cycle of human leukemic blast cells in vivo
2. G1 events and regulation of cell proliferation
3. Perspective: Defects in cell cycle control and cancer
4. The hallmarks of cancer
5. The Pezcoller lecture: Cancer cell cycle revisited
6. Proliferation, cell cycle and apoptosis in cancer
7. Apoptosis in cancer therapy: Crossing the threshold
8. Apoptosis in cancer
9. Exploiting cancer cell cycling for selective protection of normal cells
10. Anticancer drug targets: Cell cycle and checkpoint control
11. Choosing anticancer drug, targets in the postgenomic era
12. Taking aim at novel molecular targets in cancer therapy
13. Mechanism-based target identification and drug discovery in cancer
14. Cell cycle molecular targets and drug discovery
15. The multistep nature of cancer
16. Depletion of ErbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity
17. Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus
18. Inhibition of HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation
19. Stress-inducible responses and heat shock proteins: New pharmacologic targets for cytoprotection
20. Heat shock proteins - Modulators of apoptosis in tumour cells
21. Hsp90: A specialized but essential protein-folding tool
22. Hsp90: Chaperoning signal transduction
23. Role of the heat shock response and molecular chaperones in oncogenesis and cell death
24. Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent
25. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation
26. Genetic and biochemical analysis of p23 and ansamycin antibiotics in the function of Hsp90-dependent signaling proteins
27. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin
28. In vivo ubiquitination and proteasome-mediated degradation of p53
29. Regulation of the G1 to S transition by the ubiquitin pathway
30. Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases
31. Polyubiquitination and proteasomal degradation of the p185(c-erb8-2) receptor protein-tyrosine kinase induced by geldanamycin
32. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts
33. Activation of the cell death program by inhibition of proteasome function
34. Proteasome inhibitors: A novel class of potent and effective antitumor agents
35. Protease inhibitor-induced apoptosis: Accumulation wt p53, p21WaF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition
36. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy
37. Proteasome-dependent regulation of p21WAF1/CIP1 expression
38. Regulation of p53 stability by Mdm2
39. Mdm2 promotes the rapid degradation of p53
40. Loss of function and p53 stabilization
41. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding
42. Geldanamycin selectively destabilizes and conformationally alters mutated p53
43. Geldanamycin-stimulated destabolization of mutated p53 is mediated by the proteasome in vivo
44. The stabilization mechanism of mutant-type p53 by impaired ubiquitination: The loss of wild-type p53 function and the hsp90 association
45. Conformation of mutated p53 requires functional HSP90
46. Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome
47. Taxol induction of p21Waf1 and p53 requires c-raf-1
48. Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins
49. Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation
50. Intracellular retention and degradation of the epidermal growth factor receptor, two distinct processes mediated by benzoquinone ansamycins
51. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-Mitogen-activated protein kinase signalling pathway
52. Hsp90-mediated folding of the lymphoid cell kinase p56lck
53. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4
54. Modulation of akt kinase activity by binding to hsp90
55. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway
56. CDK inhibitors: Positive and negative regulators of G1-phase progression
57. Potent and specific inhibition of p60v-src protein kinase both in vivo and in vitro by radicicol
58. Suppression of RAS and MOS transformation by radicicol
59. Radicicol leads to selective depletion of Raf kinase and disrupts K-Ras-activated aberrant signaling pathway
60. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules
61. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol
62. Anticancer drug targets: Growth factors and growth factor signaling
63. The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors
64. Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase
65. The mitogen-activated protein kinase pathway mediates growth arrest or E1 A-dependent apoptosis in SKBr3 human breast cancer cells
66. Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells
67. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells
68. Molecular mechanisms of action of steroid/thyroid hormone receptor superfamily members
69. A model for the cytoplasmic trafficking of signalling proteins involving the hsp90-binding immunophilins and p50cdc37
70. Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells
71. Geldanamycin, a heat shock protein 90-binding benzoquinone ansamycin, inhibits steroid-dependent translocation of the glucocorticoid receptor from the cytoplasm to the nucleus
72. Heat shock protein 90-dependent (geldanamycin-inhibited) movement of the glucocorticoid receptor through the cytoplasm to the nucleus requires intact cytoskeleton
73. Destabilization of steroid receptors by heat shock protein 90-binding drugs: A ligand-independent approach to hormonal therapy of breast cancer
74. Enhanced cell differentiation when RB is hypophosphorylated and down-regulated by radicicol, a SRC-kinase inhibitor
75. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest
76. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells
77. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex
78. Geldanamycin induces cell cycle arrest in K562 erythroleukemic cells
79. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-raf-1 and represents a novel c-Raf-1 signal transduction pathway
80. Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human AML HL-60 cells
81. Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: Sequence and tumour biology matters
82. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB and schedule-dependent manner
83. Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin
84. The molecular biology of chronic myeloid leukemia
85. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents
86. BCR-ABL delays apoptosis upstream of procaspase-3 activation
87. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3
88. Serine/threonine phosphorylation in cytokine signal transduction
89. The HSP90 antagonist geldanamycin alters chaperone association with p210BCR-ABL and v-src proteins prior to their degradation by the proteasome
90. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
91. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
92. Clinical resistance to ST1-571 cancer therapy caused by BCR-ABL gene mutation or amplification
93. Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571
94. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation
95. In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor
96. Unusual expression and localization of heat-shock proteins in human tumor cells
97. The molecular chaperone Hsp90 is required for signal transduction by wild-type Hck and maintenance of its constitutively active counterpart
98. Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: Antiproliferative activity on human breast carcinoma cell lines
99. Use of an antibody to target geldanamycin
100. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90
101. Radicicol and geldanamycin prevent neurotoxic effects of anti-cancer drugs on cultured embryonic sensory neurons
102. Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells
103. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents
104. Induction of hsp 72/73 by herbimycin A, an inhibitor of transformation by tyrosine kinase oncogenes
105. Specific induction of the 70-kD heat stress proteins by the tyrosine kinase inhibitor herbimycin-A protects rat neonatal cardiomyocytes. A new pharmacological route to stress protein expression?
106. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice
107. Depletion of Raf-1 protooncogene by geldanamycin causes apoptosis in human luteinized granulosa cells
108. Demethoxygeldanamycin (AAG) in adult patients with advanced solid tumors
109. Phase I trial of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) in patients (Pts) with advanced solid malignancies
110. Phase I trial of the heat shock protein 90 (HSP90) inhibitor 17-allylamino 17-demethoxygeldanamycin 17 aag) Pharmacokinetic (PK) profile and pharmacodynamic (PD) endpoints
111. Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer
112. Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies
113. DMSO-like rapid decrease in c-myc and c-myb mRNA levels and induction of differentiation in HL-60 cells by the anthracycline antitumor antibiotic aclarubicin
114. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins
115. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity
116. Don't stop for repair in a war zone: Darwinian evolution unites genes and environment in cancer development